N-cbz-2-吗啉羧酸 | 135782-21-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-cbz-2-吗啉羧酸
• 中文别名: N-Cbz-2-吗啉甲酸
• 英文名称: 4-((benzyloxy)carbonyl)morpholine-2-carboxylic acid
• 英文别名: 4-phenylmethoxycarbonylmorpholine-2-carboxylic acid
• CAS: 135782-21-7
• 化学式: C₁₃H₁₅NO₅
• mdl: MFCD16223609
• 分子量: 265.266
• InChiKey: AVQCLRKABAZVMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  464.3±45.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N-cbz-2-吗啉羧酸 在 pyridinium hydrobromide perbromide 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.08h， 生成
  参考文献：
  名称：

  苯并吡喃酮类化合物、其制备方法及其应用

  摘要：

  本发明提供了一种式(I)所示的苯并吡喃酮类化合物或其药学上可接受的盐、制备方法和用途。该类化合物对POLRMT具有良好抑制作用，可用于治疗和/或预防由POLRMT介导的癌症等疾病。

  公开号：

  WO2024114765A1

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2009011A1

  公开（公告）日：2008-12-31

  The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties such as efficacy, duration of activity, specificity, low toxicity and the like. The present invention provides a compound represented by the following formula wherein ring M is a 5- or 6-membered aromatic ring; W is C or N; K is an optionally substituted methylene group or an optionally substituted imino group; R is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted heterocyclic group; T and U are independently a hydrogen atom or a substituent or, T and U form, together with ring M, an optionally substituted bicyclic ring; D and G are independently a carbonyl group or a sulfonyl group; ring P is an optionally substituted piperidine or an optionally substituted piperazine; B is CH or N; ring Q is an optionally substituted monocyclic ring; A is C, CH or N; and J is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted amino group, provided that when the W moiety of ring M is =N- or -N=, then U should be absent, or a salt thereof.

  本发明的目的是提供一种具有ACC抑制作用的化合物，用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等疾病，并具有诸如疗效、活性持续时间、特异性、低毒性等优越特性。本发明提供了以下式所表示的一种化合物，其中环M为5-或6-成员芳香环；W为C或N；K为可选择地取代的亚甲基基团或可选择地取代的亚胺基团；R为氢原子、可选择地取代的碳氢基团、可选择地取代的羟基或可选择地取代的杂环基团；T和U独立地为氢原子或取代基，或T和U与环M一起形成可选择地取代的双环环；D和G独立地为羰基或磺酰基；环P为可选择地取代的哌啶或可选择地取代的哌嗪；B为CH或N；环Q为可选择地取代的单环环；A为C、CH或N；J为可选择地取代的碳氢基团、可选择地取代的杂环基团或可选择地取代的氨基团，前提是当环M的W基团为=N-或-N=时，U应当不存在，或其盐。
• Compounds and compositions for treating obesity
  申请人：Conde-Frieboes Waldemar Kilian

  公开号：US20070185128A1

  公开（公告）日：2007-08-09

  Described herein are novel and useful compounds of the general formula Compounds of this invention can advantageously exhibit melanocortin receptor agonist activity. New and useful compounds comprising such a chemical structure and methods of modulating melanocortin receptor activity in a subject (and promoting, inducing, and/or enhancing the treatment or prevention of related diseases) by administering such a compound or composition also are described.

  本文描述了一种新颖且有用的化合物，其一般公式为。本发明的化合物可以有利地表现为黑色素皮质素受体激动剂活性。还描述了包含这种化学结构的新型和有用的化合物，以及通过给予这种化合物或组合物来调节受体在受试者中的活性（并促进、诱导和/或增强相关疾病的治疗或预防）的方法。
• Kinase inhibitory phosphonate analogs
  申请人：Cannizzaro Carina

  公开号：US20050261253A1

  公开（公告）日：2005-11-24

  The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及磷取代的激酶抑制化合物、含有这些化合物的组合物、包括给予这些化合物的治疗方法，以及用于制备这些化合物的过程和中间体。
• Anti-inflammatory phosphonate compounds
  申请人：Cannizzaro Carina

  公开号：US20060199788A1

  公开（公告）日：2006-09-07

  The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及磷取代的抗炎化合物、含有这些化合物的组合物、包括这些化合物的给药治疗方法，以及用于制备这些化合物的过程和中间体。
• ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS
  申请人：Cannizzaro Carina

  公开号：US20090247488A1

  公开（公告）日：2009-10-01

  The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗炎化合物、含有这种化合物的组合物、包括给药这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。